Yasir Al-Wakeel
Director/Board Member bij MAXCYTE, INC.
Vermogen: 449 933 $ op 31-03-2024
Profiel
Yasir Baha Al-Wakeel is an Independent Non-Executive Director at MaxCyte, Inc. He previously worked as Treasurer, Chief Financial & Accounting Officer at Merrimack Pharmaceuticals, Inc. and as a Research Analyst at Credit Suisse Securities (Europe) Ltd.
He also served as the Chief Financial Officer at BioNTech US, Inc. and currently holds the position of CFO, CAO & Head-Corporate Development at Kronos Bio, Inc. Dr. Al-Wakeel holds a doctorate degree from the University of Oxford and a graduate degree from the University of Cambridge.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
KRONOS BIO INC
0.58% | 06-07-2023 | 346 102 ( 0.58% ) | 449 933 $ | 31-03-2024 |
MAXCYTE, INC.
-.--% | 22-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Yasir Al-Wakeel
| Bedrijven | Functie | Begin |
|---|---|---|
| MAXCYTE, INC. | Director/Board Member | 15-06-2021 |
Eerdere bekende functies van Yasir Al-Wakeel
| Bedrijven | Functie | Einde |
|---|---|---|
| KRONOS BIO, INC. | Director of Finance/CFO | 15-09-2023 |
| NEON THERAPEUTICS, INC. | Director of Finance/CFO | 01-05-2020 |
| MERRIMACK PHARMACEUTICALS, INC. | Director of Finance/CFO | 01-07-2017 |
Credit Suisse Securities (Europe) Ltd.
 Credit Suisse Securities (Europe) Ltd. Investment ManagersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Analyst-Equity | 01-06-2015 |
Opleiding van Yasir Al-Wakeel
| University of Oxford | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MAXCYTE, INC. | Health Technology |
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| KRONOS BIO, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Credit Suisse Securities (Europe) Ltd.
Credit Suisse Securities (Europe) Ltd. Investment ManagersFinance Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors. | Finance |
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
